Interpreting Lymphocyte Reconstitution Data From the Pivotal Phase 3 Trials of Alemtuzumab
View/ Open
Accepted version
Embargoed until: 5555-01-01
Reason: Publisher does not permit archiving
Embargoed until: 5555-01-01
Reason: Publisher does not permit archiving
Volume
74
Pagination
961 - 969
DOI
10.1001/jamaneurol.2017.0676
Journal
JAMA NEUROLOGY
Issue
ISSN
2168-6149